EntryPoint Capital’s GoodRx Holdings GDRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$156K Buy
+54,271
New +$138K 0.04% 720
2025
Q4
Sell
-31,425
Closed -$133K 735
2025
Q3
$133K Sell
31,425
-46,382
-60% -$204K 0.05% 604
2025
Q2
$387K Buy
77,807
+18,887
+32% +$82K 0.19% 177
2025
Q1
$260K Buy
58,920
+46,826
+387% +$220K 0.12% 407
2024
Q4
$56.2K Buy
+12,094
New +$66.5K 0.02% 687
2024
Q2
Sell
-18,538
Closed -$132K 1576
2024
Q1
$132K Buy
18,538
+11,548
+165% +$76.4K 0.12% 284
2023
Q4
$46.8K Buy
+6,990
New +$39.4K 0.04% 754

Other funds holding GDRX

EntryPoint Capital's GDRX Position: Q2 2026 in Review

EntryPoint Capital opened a new position in GoodRx Holdings (GDRX) in Q2 2026: 54,271 shares worth $156K. The stake represents 0.04% of the portfolio and ranks #720 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in GDRX as recently as Q3 2025.

EntryPoint Capital first reported a position in GDRX in Q4 2023 and has held it in 7 quarters since. The position peaked at $387K in Q2 2025. 162 funds tracked by Wall St. Rank hold GDRX as of Q2 2026.

  • EntryPoint Capital held 54,271 shares of GoodRx Holdings worth $156K as of Q2 2026.
  • GoodRx Holdings was a new EntryPoint Capital position in Q2 2026.
  • GoodRx Holdings made up 0.04% of EntryPoint Capital's portfolio in Q2 2026, its #720 holding.
  • EntryPoint Capital first reported a position in GoodRx Holdings in Q4 2023 and has held it in 7 quarters since.
  • EntryPoint Capital's GoodRx Holdings position peaked at $387K in Q2 2025.
  • 162 funds tracked by Wall St. Rank held GoodRx Holdings as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.